A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit*
- 1 February 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 38 (2), 497-503
- https://doi.org/10.1097/ccm.0b013e3181bc81c9
Abstract
To compare the intensive care unit costs and determine factors influencing these costs in mechanically ventilated patients randomized to dexmedetomidine or midazolam by continuous infusion. Cost minimization analysis of a double-blind, multicenter clinical trial randomizing patients 2:1 to receive dexmedetomidine or midazolam from the institutional perspective. Sixty-eight intensive care units in the United States, Australia, New Zealand, Brazil, and Argentina. A total of 366 intubated intensive care unit patients anticipated to require sedation for >24 hrs. Intensive care unit resource use was compared within the two treatment arms, using the U.S. representative costs for these resources. The analyses characterized patient costs from start of study drug until intensive care unit discharge including costs associated with the intensive care unit stay, costs during mechanical ventilation, study drug acquisition cost, and costs of treating adverse drug reactions probably or possibly related to study drugs. Blinded to treatment group, costs were calculated using Medicare reimbursement schedules, average IMS drug costs, expert opinion, and peer-reviewed literature. Censored lengths of intensive care unit stay and mechanical ventilation were imputed, using a nonparametric adjustment algorithm. Crude and multivariate median regressions were performed to relate intensive care unit cost and treatment. Including drug acquisition cost, sedation with dexmedetomidine was associated with a median total intensive care unit cost savings of $9679 (confidence interval, $2314-$17,045) compared with midazolam. The primary cost drivers were reduced costs of intensive care unit stay (median savings, $6584, 95% confidence interval, $727-$12,440) and reduced costs of mechanical ventilation (median savings, $2958, 95% confidence interval, $698-$5219). Continuous sedation with dexmedetomidine results in significantly lower total intensive care unit costs compared with midazolam infusion for intensive care unit sedation, primarily due to decreased intensive care unit stay costs and reduced mechanical ventilation costs.This publication has 26 references indexed in Scilit:
- An Analgesia–Delirium–Sedation Protocol for Critically Ill Trauma Patients Reduces Ventilator Days and Hospital Length of StayThe Journal of Trauma and Acute Care Surgery, 2008
- Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation*Critical Care Medicine, 2008
- Economic evaluation of sustained sedation/analgesia in the intensive care unitExpert Opinion on Pharmacotherapy, 2006
- Sedation in the mechanically ventilated patientCritical Care Medicine, 2006
- Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressureStatistics in Medicine, 2005
- Economic evaluation of new therapies in critical illnessCritical Care Medicine, 2003
- Quantile RegressionJournal of Economic Perspectives, 2001
- Delirium in the Intensive Care Unit: An Under-Recognized Syndrome of Organ DysfunctionSeminars in Respiratory and Critical Care Medicine, 2001
- Evidence for a Gene Influencing Blood Pressure on Chromosome 17Hypertension, 2000
- Continuous infusion of lorazepam versus midazolam in patients in the intensive care unitCritical Care Medicine, 1999